Amyloidosis




Risk





  • Incidence in USA: 1:100,000



  • Race with highest prevalence: Unknown





Perioperative Risks





  • Increased risk of periop renal failure, cardiomyopathy (arrhythmias and ventricular dysfunction), bleeding from coagulopathy



  • Autonomic neuropathy





Perioperative Risks





  • Increased risk of periop renal failure, cardiomyopathy (arrhythmias and ventricular dysfunction), bleeding from coagulopathy



  • Autonomic neuropathy





Worry About





  • Signs of CHF



  • Dysrhythmias



  • Decreasing urine output





Overview





  • Extracellular deposition of amyloid-type proteins.



  • Congo-red stain of tissue reveals green birefringence in a polarizing microscope.



  • Associated end-stage renal, myocardial, and neuropathic disease.



  • Best diagnosed by subcutaneous abdominal fat pad aspirate or rectal biopsy.





Etiology





  • Both acquired and hereditary forms exist.



  • Acquired forms are categorized as primary (AL), associated with plasma cell disorders (i.e., multiple myeloma), and secondary (AA), associated with inflammatory and infectious diseases (e.g., osteomyelitis, rheumatoid arthritis).



  • Hereditary forms very rare.





Usual Treatment





  • Acquired: Treatment of primary (AL) amyloidosis is directed at the underlying plasma cell disorder (e.g., chemotherapy, stem cell transplant). Treatment of secondary (AA) amyloidosis is directed at underlying infection/inflammation.



  • Hereditary: Colchicine, liver transplantation.



  • Treatments to clear amyloid deposits are being developed.


Only gold members can continue reading. Log In or Register to continue

Sep 1, 2018 | Posted by in ANESTHESIA | Comments Off on Amyloidosis

Full access? Get Clinical Tree

Get Clinical Tree app for offline access